Zenshine Pharma Raised $15 Million in Series A Financing
Date / 2021.02.05
Zenshine pharma closed a $15 Million Series A financing in December 2020. The round was led by Summit Capital. A group of venture funds including Ennovation Ventures, Indaco Capital, Jiuyo Capital, and Dingzhu Technology also participated in the round. The funds will be used to further develop its pipeline of best-in-class and first-in-class therapeutics for the treatment of cancer, infectious and inflammatory diseases.  Zenshine pharma received its first round investment of $5 million from Ennovation Ventures in July 2018.

About Zenshine Pharma
Zenshine Pharma, a clinical stage company focused on discovery and development of innovative therapeutics for the treatment of cancer, infectious and inflammatory diseases, was founded in 2018 by industry veterans Jinfu Yang and Xiaolin Hao. Zenshine’s management team has extensive experience and expertise in drug discovery and development and successfully brought over a dozen compounds to the clinic and on the market. 
Our mission is to apply the best science to serve patients. By targeting key biological pathways to disrupt virus replication, directly block tumor growth and enhance anti-tumor immune responses, Zenshine commits to providing bench-side to bed-side solutions and delivering the best-in-class or first-in-class therapeutics. We expect our first product to be approved and commercialized around 2024.

Back to list